Thomas Cannell

Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA.

Part of Merck & Co., Inc., MSD (Japan) Co., Ltd. is a company that focuses on Japanese domestic development pipeline. The private company is based in Tokyo, Japan. The company's description states that it is a page of the clinical trial guide, which suggests that it is involved in the development and testing of new pharmaceutical products.

Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Part of Merck & Co., Inc., Merck Canada, Inc. is a Canadian biopharmaceutical company that has been inventing medicines and vaccines for over 130 years. The private company is based in Kirkland, Canada and is committed to increasing access to healthcare through policies, programs, and partnerships. Merck Canada continues to be at the forefront of research to prevent and treat diseases such as cancer, HIV, and Ebola. The company aspires to be the premier research-intensive biopharmaceutical company in the world. Marwan Akar has been the CEO of the company since 1997.